Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von fchar99 

Alnylam Pharmace. diskutieren

Alnylam Pharmace.

WKN: A0CBCK / Symbol: ALNY / Name: Alnylam Pharms / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /

226,90 €
-1,08 %

Einschätzung Buy
Rendite (%) 62,07 %
Kursziel 186,38
Veränderung
Endet am 02.05.25

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $200.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat

Einschätzung Buy
Rendite (%) 61,84 %
Kursziel 371,08
Veränderung
Endet am 07.05.25

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at HC Wainwright from $395.00 to $400.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat

Einschätzung Buy
Rendite (%) 7,69 %
Kursziel 218,11
Veränderung
Endet am 24.06.25

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $234.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat

Einschätzung Buy
Rendite (%) 7,69 %
Kursziel 372,84
Veränderung
Endet am 24.06.25

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat

Einschätzung Buy
Rendite (%) 9,09 %
Kursziel 256,11
Veränderung
Endet am 24.06.25

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Needham & Company LLC from $200.00 to $275.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat

Einschätzung Buy
Rendite (%) 2,62 %
Kursziel 233,58
Veränderung
Endet am 25.06.25

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Royal Bank of Canada from $235.00 to $250.00. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat

Einschätzung Buy
Rendite (%) 2,62 %
Kursziel 271,88
Veränderung
Endet am 25.06.25

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Barclays PLC from $236.00 to $291.00. They now have an "overweight" rating on the stock.
Ratings data for ALNY provided by MarketBeat

Einschätzung Buy
Rendite (%) 2,62 %
Kursziel 242,92
Veränderung
Endet am 25.06.25

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Evercore ISI from $210.00 to $260.00. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat

Einschätzung Buy
Rendite (%) 2,16 %
Kursziel 263,30
Veränderung
Endet am 25.06.25

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at TD Cowen from $260.00 to $282.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat

Einschätzung Buy
Rendite (%) 1,98 %
Kursziel 275,35
Veränderung
Endet am 25.06.25

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Bank of America Co. from $248.00 to $295.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,84 %
Kursziel 271,50
Veränderung
Endet am 25.06.25

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Citigroup Inc. from $227.00 to $291.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat

Einschätzung Buy
Rendite (%) -0,79 %
Kursziel 275,15
Veränderung
Endet am 27.06.25

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Stifel Nicolaus from $215.00 to $295.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat

Einschätzung Buy
Rendite (%) -0,48 %
Kursziel 268,93
Veränderung
Endet am 28.06.25

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at UBS Group AG from $253.00 to $288.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat